Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma

FcRH5 is a cell surface marker enriched on malignant plasma cells when compared to other hematologic malignancies and normal tissues. DFRF4539A is an anti-FcRH5 antibody-drug conjugated to monomethyl auristatin E (MMAE), a potent anti-mitotic agent. This phase I study assessed safety, tolerability,...

Descripción completa

Detalles Bibliográficos
Autores principales: Stewart, A. Keith, Krishnan, Amrita Y., Singhal, Seema, Boccia, Ralph V., Patel, Manish R., Niesvizky, Ruben, Chanan-Khan, Asher A., Ailawadhi, Sikander, Brumm, Jochen, Mundt, Kirsten E., Hong, Kyu, McBride, Jacqueline, Shon-Nguyen, Quyen, Xiao, Yuanyuan, Ramakrishnan, Vanitha, Polson, Andrew G., Samineni, Divya, Leipold, Douglas, Humke, Eric W., McClellan, James Scott, Berdeja, Jesus G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362066/
https://www.ncbi.nlm.nih.gov/pubmed/30718503
http://dx.doi.org/10.1038/s41408-019-0178-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362066/
https://www.ncbi.nlm.nih.gov/pubmed/30718503
http://dx.doi.org/10.1038/s41408-019-0178-8

Ejemplares similares